期刊文献+

奥沙利铂联合卡培他滨治疗进展期胃癌的临床研究 被引量:16

下载PDF
导出
摘要 目的观察奥沙利铂联合卡培他滨新辅助治疗进展期胃癌的疗效和不良反应;回顾性调查研究奥沙利铂联合卡培他滨新辅助治疗进展期胃癌对手术的影响。方法选取株洲市一医院2006年1月至2010年1月收治的进展期胃癌患者52例为治疗组;选取株洲市一医院2003年12月至2005年12月收治的进展期胃癌患者44例为对照组;肿瘤术前分期均为TNMⅢ~Ⅳ期,治疗组给予奥沙利铂联合卡培拉宾新辅助化疗,3周为1个疗程,2个周期后评价治疗效果,施行手术,术后继续上述化疗4~6个周期。对照组直接施行手术,术后化疗4~6个周期。评价奥沙利铂联合卡培他滨新辅助化疗的效果;比较进行新辅助化疗对提高手术切除率和根治度的作用。结果治疗组52例,50例完成治疗过程,并进行疗效评价,完全缓解3例,部分缓解17例,疾病稳定26例,疾病进展4例,近期有效率为40.0%,中位生存期为23个月。治疗组45例行手术治疗;对照组33例行手术治疗。不良反应主要为神经毒性、手足综合征、骨髓抑制、恶心呕吐等,多为Ⅰ~Ⅱ度。结论①奥沙利铂联合卡培他滨治疗进展期胃癌效果较好,不良反应可耐受;②奥沙利铂联合卡培拉宾应用于新辅助化疗可以明显提高手术切除率和根治度。
出处 《中国医药指南》 2011年第8期70-72,共3页 Guide of China Medicine
  • 相关文献

参考文献5

  • 1金懋林.进展期胃癌全身化学治疗研究新进展[J].癌症进展,2007,5(1):18-24. 被引量:82
  • 2鄢践.实体瘤疗效评定最新指南[J].国外医学·肿瘤分册,2000,27(6):375-375.
  • 3Takiuehi H,Goto M,Kawabe S,et al.Second·line chemotherapy ingasric cancer[J].Can To Kagaku Ryoho,2005,32(1):19-23.
  • 4张剑军,徐惠绵,王振宁,赵宜良,杨巍,郑志超,谷小虎,张涛,刘勇,刘彦擎.进展期胃癌新辅助化疗临床疗效分析[J].山东医药,2010,50(4):87-88. 被引量:8
  • 5Okines AF,Norman AR,MaCloud P,et al.Meta-analysis of the REAL-2 and ML17032 trials:evaluating capeeitabine based combination chemotherapy and infused 5-fluorouracil based combination chemotherapy for the treatment of advanced oesophagogastric cancer[J].Ann Oncol,2009,20(9):1529-1534.

二级参考文献13

  • 1沈琳,李洁,张晓东,李燕,张小田,金懋林.PELF方案治疗进展期胃癌68例[J].中国肿瘤临床,2005,32(3):162-164. 被引量:19
  • 2Yasuhiro Kodera,Michitaka Fujiwara,Masahiko Koike,Akimasa Nakao.Chemotherapy as a component of multimodal therapy for gastric carcinoma[J].World Journal of Gastroenterology,2006,12(13):2000-2005. 被引量:12
  • 3[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
  • 4[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
  • 5[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
  • 6[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43
  • 7[7]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660
  • 8[9]Cunningham D,Rao S,Starling N,et al.Randomised multicentie phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patientswith advanced oesophagogastric cancer:The REAL 2 trial.Proc Am Soc Clin Oncol,2006,24:182S
  • 9[10]Park Y,Lee J,Ryoo B,et al.Aphase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.Proc Am Soc Clin Oncol,2006,24:197S
  • 10[11]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophagealjunction adenocarcin oma:Final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2000,20:531

共引文献97

同被引文献98

  • 1黄雪珍,吴晖,王剑峰,毛雪华,何勇.优福定、依托泊甙、顺铂(FEP方案)与5-氟尿嘧啶、阿霉素、丝裂霉素(FAM方案)治疗晚期胃癌临床对照研究[J].新药与临床,1994,13(6):325-327. 被引量:2
  • 2Spitzer WO,Dobson AJ,Hall J,et al.Measuring the quality of life of cancer patients:a concise QL-index for use by physicians.J Chronic Dis,1981,34:585-597.
  • 3Cunningham D, Jost LM, Purkalne G, et al. ESMO minimum clini- cal recommendations for diagnosis, treatment and follow-up of gas- tric cancer[ J ]. Ann Onco1,2005,16 ( Suppl 1 ) : i22 - i23.
  • 4Rino Y,Yukawa N,Sato T,et al. Phase II study on the combination of irinotecanplus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer [ J ]. Mol Clin Oncol, 2013,1 (4) :749 -752.
  • 5Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX) plus sup- portive care with supportive care alone in patients with non-resect- able gastric cancer[J]. Br J Cancer,1995,71 (3) :587 -591.
  • 6Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in ad- vanced gastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24( 18 ) :2903 -2909.
  • 7A1-Batran SE, Hartmann F, Probst S, et al. Phase RI trial in meta- static gastrophgeal adenocarcinoma with fluorouracil, leucovorirt plus either oxaliplatin or cisplatin: a study of the Arbeitsgemein- schaft Internlstisehe Onkologie [ J ]. J Clin Oncol, 2008,26 ( 9 ) : 1435 - 1442.
  • 8Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxali- platin and the use of pharmacogenomics to individualize therapy [ J]. Cancer Treat Rev,2005,31 (2) :90 - 105.
  • 9Cunningham D, Starling N, Rao S. Capecitabine and oxaliplatin for advanced esophagogastric cancer[ J]. N Engl J Med, 2010,362 (9) :858 -859.
  • 10Pozzo C, Barone C. ls there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a plat- form for the introduction of new biological agents? [ J ]. Oncologist,2008,13 (7) :794 - 806.

引证文献16

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部